

Saturday (26.10.2024)	Sunday (27.10.2024)	Monday (28.10.2024)	
<p>08:30-11:00 Working towards harmonization of clinical trial reporting in Hodgkin Lymphoma (Chairs: S. Barrington, S. Borchmann, C. Kobe, W. Plattel, D. Rossi)</p> <p>Separate registration required</p> <p>08:30-11:00 EHA-LYG/GHSG Joint Educational: "Emerging Therapeutic Concepts in B-Cell Lymphomas" (Chairs: I. Aurer, B. von Tresckow)</p> <ul style="list-style-type: none"> Molecular and microenvironmental vulnerabilities of B-cell Lymphomas (S. Leppä) Is there a role for CAR T-cell therapy in first-line Tx of indolent lymphoma? (M. Kersten) Who needs bispecific antibodies as first-line treatment in aggressive lymphoma? (C. Thieblemont) How to implement novel ADCs in the first-line treatment of lymphoma (P. Zinzani) Perspectives of small molecule based first-line therapy of LBCL (T. Vassilakopoulos) Treatment and Trial Landscape for Malignant Lymphoma in China (Y. Song) <p>Break</p> <p>11:30-13:00 Limited Stages (Chairs: M. André, L. Specht)</p> <ul style="list-style-type: none"> Intro: Treatment concepts in early-stage HL (M. André) Viewpoint: Systemic therapy only in the future? (R. Advani) Viewpoint: CMT (Is it there to stay?) (J. Yahalom) <p>Break</p> <p>13:15-14:45 The evolving role of BTKis in the treatment of B-cell lymphomas by BeiGene Switzerland GmbH, (Chair: C. Buske)</p> <ul style="list-style-type: none"> Welcome and Introduction (C. Buske) BTKis in indolent lymphomas (FL, MZL) (C. Thieblemont) BTKis in WM (C. Buske) BTKis in MCL (D. Lewis) Future developments (CDAC, BCL2, anti PD1/PDL1) (A. Frustaci) Panel discussion, audience Q&A (All) Closure and farewell (C. Buske) <p>Break</p> <p>15:15-17:00 Opening and Award Ceremony Keynote Lecture: Linda Partridge</p> <p>Break</p> <p>17:15-20:00 Poster Session with Welcome Reception</p>	<p>08:00-09:30 Pediatric and Adolescent Treatment Concepts (Chairs: J. Friedberg, C. Mauz-Körholz)</p> <ul style="list-style-type: none"> Recent achievements and future goals in Pediatric and Young Adult HL <ul style="list-style-type: none"> COG Perspective (S. Castellino) EuroNET-PHL Perspective (C. Mauz-Körholz) Appropriate endpoints for future trials in Pediatric and Young Adult HL, and opportunities for harmonization (J. Flertage) <p>Break</p> <p>10:00-11:30 Biology & Microenvironment (Chairs: S. Leppä, M. Shipp)</p> <ul style="list-style-type: none"> Pathogenesis of HL (R. Küppers) Multimodal characterization of cHL (C. Steidl) <p>Break</p> <p>12:00-13:30 New concepts for the treatment of B-cell lymphomas by MSD Sharp & Dohme GmbH (Chair: P. Borchmann)</p> <ul style="list-style-type: none"> B-cell lymphoma pathology - illustrated for non-pathologists (W. Klapper) Classical Hodgkin Lymphoma - Development of immune checkpoint inhibition beyond PD-1 blockade (P. Borchmann) Diffuse Large B-cell Lymphoma - The current and future role of ADC in the context of immunotherapy (S. Dietrich) <p>Break</p> <p>14:00-15:30 Older Patients (Chairs: P. Bröckelmann, A. Evens)</p> <ul style="list-style-type: none"> Implementing Frailty Assessment for Treatment Guidance in HL (S. Rutherford) Optimal Use of Targeted Agents to Address Unmet Need in Older HL (G. Collins) <p>Break</p> <p>16:00-17:30 Real world impact: bridging between clinical trial and real world experience in stages III & IV 1L Hodgkin Lymphoma by Takeda Pharmaceuticals USA, Inc. (Chair: J. Radford)</p> <ul style="list-style-type: none"> Spotlight on ECHELON-1: 7-year survival data (J. Radford) Real-world insights: frontline treatment of stages III & IV cHL (C. Rusconi) Q&A (All faculty) cHL in the real-world: a case study approach (C. Mahuad, J. Radford) <p>Break</p> <p>18:00-19:30 Advanced Stages (Chairs: A. Herrera, J. Zijlstra)</p> <ul style="list-style-type: none"> Individualized treatment de-escalation improves overall outcomes (P. Borchmann) Immune-chemotherapy overcomes the need for individualization (J. Friedberg) 	<p>08:00-09:00 Special Situations & Cases (Chairs: A. Fosså, A. Sureda)</p> <ul style="list-style-type: none"> Treatment Approaches in Resource Constraint Settings (Speaker: O. Balocchi, Discussant: C. Asirwa) HL Richter Transformation (S. Hartmann, M. Hertzberg, O. Al-Sawaf) <p>Break</p> <p>09:15-10:15 NLPHL (Chairs: R. Hoppe, W. Klapper)</p> <ul style="list-style-type: none"> NLPHL: HL, NHL or something else? (S. Hartmann) First-line treatment of NLPHL with HL-directed approaches (D. Eichenauer) Treatment of NLPHL with NHL-directed approaches (G. Collins) <p>Break</p> <p>10:30-12:00 Living Beyond Lymphoma (Chairs: F. van Leeuwen, J. Radford)</p> <ul style="list-style-type: none"> Late consequences of drugs used in the modern era of treatment for HL (S. Ansell) Starting Living beyond Lymphoma with HL diagnosis (K. Behringer, M. Büttner) Participation in and (cost-)effectiveness of the Dutch HL survivorship care program (A. Nijdam, B. Aleman) <p>Break</p> <p>12:30-14:00 Relapsed / Refractory HL (Chairs: P. Armand, C. Moskowitz)</p> <ul style="list-style-type: none"> Updated approach to second-line treatment (A. Moskowitz) Emerging strategies to overcome anti-PD1 resistance (S. Ansell) Implementing radiotherapeutic concepts in rHL care (C. Baues) <p>14:00-15:00 Closing Session</p> <ul style="list-style-type: none"> WS Report (S. Barrington, S. Borchmann, C. Kobe, W. Plattel, D. Rossi) Best of ISHL13 (R. Advani) Farewell (P. Borchmann) 	<p>08:00</p> <p>09:15</p> <p>10:00</p> <p>10:30</p> <p>12:00</p> <p>12:30</p> <p>14:00</p> <p>15:00</p> <p>16:00</p> <p>17:15</p> <p>18:00</p>